Deciphera Pharmaceuticals Inc (NASDAQ:DCPH)
| 13.47 Delayed Data As of 3:59pm ET |  +0.12 / +0.90%Today’s Change | 6.51 Today|||52-Week Range 37.99 | +37.87% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Biotechnology | MARKET CAP $911.1M |
Company Description
Deciphera Pharmaceuticals, Inc. engages in discovering, developing, and delivering important new medicines to patients for the treatment of cancer. The firm designs a drug candidate, DCC-2618, to inhibit the full spectrum of mutant or amplified KIT and PDGFRa kinases that drive cancers such as gastrointestinal stromal tumors (GIST), advanced systemic mastocytosis (ASM), gliomas, and other solid tumors. It also develops two other clinical-stage drug candidates, DCC-3014 and rebastinib, as immuno-oncology kinase, inhibitors targeting the kinases CSF1R, and TIE2 kinas. The company was founded by Peter A. Petillo and Daniel L. Flynn in November 2003 and is headquartered in Waltham, MA.
Contact Information
Deciphera Pharmaceuticals, Inc. 200 Smith Street Waltham Massachusetts 02451 |
Employees
Shareholders
| Other institutional | 35.79% |
| Individual stakeholders | 33.86% |
| Mutual fund holders | 30.29% |
Top Executives
| Steven L. Hoerter | President & Chief Executive Officer |
| Tucker Kelly | Chief Financial Officer, Treasurer & Executive VP |
| Daniel L. Flynn | Chief Scientific Officer & Executive VP |
| Rodrigo Ruiz Soto | Senior Vice President-Clinical Development |
| Stephen B. Ruddy | Chief Technical Officer & SVP |
